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Alzheimer’s disease (AD) is a complex disorder that affects the central nervous system
causing a severe neurodegeneration. This pathology affects an increasing number of
people worldwide due to the overall aging of the human population. In recent years SUMO
protein modification has emerged as a possible cellular mechanism involved in AD. Some
of the proteins engaged in the physiopathological process of AD, like BACE1, GSK3-β tau,
AβPP, and JNK, are in fact subject to protein SUMOmodifications or interactions. Here, we
have investigated the SUMO/deSUMOylation balance and SUMO-related proteins during
the onset and progression of the pathology in the Tg2576 mouse model of AD. We
examined four age-stages (1.5, 3, 6, 17 months old) and observed shows an increase
in SUMO-1 protein conjugation at 3 and 6 months in transgenic mice with respect
to WT in both cortex and hippocampus. Interestingly this is paralleled by increased
expression levels of Ubc9 and SENP1 in both brain regions. At 6 months of age also the
SUMO-1 mRNA resulted augmented. SUMO-2-ylation was surprisingly decreased in old
transgenic mice and was unaltered in the other time windows. The fact that alterations
in SUMO/deSUMOylation equilibrium occur from the early phases of AD suggests that
global posttranslational modifications may play an important role in the mechanisms
underlying disease pathogenesis, thus providing potential targets for pharmacological
interventions.
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INTRODUCTION
Alzheimer’s disease (AD) is considered one of the most com-
mon and debilitating pathologies in the elderly. AD is a slowly
progressive neurodegenerative disease that is characterized by
impairment of memory and eventually by other symptoms (Heun
et al., 2013).
Research indicates that the disease is associated with the pro-
duction of oligomers of amyloid beta (Aβ) leading to progressive
neuritic plaque deposition and hyperphosphorylation of micro-
tubule protein tau with subsequent formation of neurofibrillary
tangles (Tiraboschi et al., 2004).
An “oxidative stress hypothesis” for AD has been recently pos-
tulated (Markesbery, 1997; Di Domenico et al., 2011; Leitao et al.,
2011), albeit it is still unclear whether oxidative stress represents a
trigger mechanism to unbalance normal cell functions or might
be rather the consequence of pathogenic events. SUMOylation
is among the PTMs that has been recently linked to AD (Lee
et al., 2013). In fact, SUMOylation induces critical changes on
AD-associated proteins like microtubule-associated protein tau
(MAPT), amyloid β precursor protein (AβPP) (Georgopoulou
et al., 2001; Marcus and Schachter, 2011), c-Jun terminal kinase
(JNK) (Feligioni et al., 2011; Sclip et al., 2013) and AMPA
receptors (Jaafari et al., 2013), that play an important role in
neuronal physiology (Pittaluga et al., 2005, 2006; Holman et al.,
2007), therefore providing novel targets for therapeutic interven-
tion. SUMO family includes at least three paralogs (SUMO-1
to -3) ubiquitously expressed in all organism tissues includ-
ing the brain (Droescher et al., 2013). SUMOs target proteins
through non-covalent or covalent interactions affecting their cel-
lular localization, aggregation, metabolism and activity (Steffan
et al., 2004; Martin et al., 2007; Feligioni et al., 2011; Krumova
et al., 2011; Droescher et al., 2013). Protein SUMOylation has
recently been recognized to play a fundamental role in oxida-
tive stress (Bossis and Melchior, 2006; Feligioni et al., 2011;
Leitao et al., 2011; Feligioni and Nisticò, 2013), in the regu-
lation of glutamate release (Feligioni et al., 2009) and also in
the modification of activity of several intracellular proteins like
AβPP and tau (Dorval and Fraser, 2006, 2007; Zhang and Sarge,
2008). As a consequence, SUMO-mediated alterations in specific
intracellular signaling pathways could promote AD pathogen-
esis. Altogether, these observations indicate that SUMOylation
could play an important role in the onset of AD, though its pre-
cise contribution still remains elusive. Here we performed an
age-related analysis on the expression levels of global protein
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SUMOylation and SUMO-related enzymes in the Tg2576 mouse
modeling AD. Importantly, we observe significant differences




All experiments were done in accordance with the European
Community Council Directive of 24 November 1986
(86/609/EEC) and approved by the Ethical Committee on
animal experiments of EBRI “Rita Levi-Montalcini” Foundation
(Rome, Italy).
BRAIN TISSUE DISSECTION
Adult male and female Tg2576 (Brecht et al., 2005) mice were sac-
rificed by cervical dislocation and immediately after hippocampal
and cortical brain regions were dissected on ice. Both Tg2576
and WT mice were processed in parallel and were used for the
experiments at the different age stages (1.5, 3, 6, and 17 months).
Once removed, brain tissues were immediately placed in a cryop-
reservation solution {containing 0.32M sucrose, buffered to pH
7.4 with Tris-(hydroxymethyl)-amino methane [Tris, final con-
centration (f.c.) 0.01M]} and stored at −80◦C until needed. The
cortical and hippocampal tissues of Tg2576 and their wild-type
(WT) littermates have been kindly provided by Lundbeck AS
(Denmark).
PREPARATION OF LYSATE FROM BRAIN TISSUE
Around 200μg of mice tissues were lysed in 300μl of
Lysis Buffer solution (LB) made up of 1% Triton X-100
(Serva, Germany), complete protease inhibitor cocktail solution
(Serva, Germany), phosphatase inhibitor cocktail solution (Serva,
Germany), 20mM of NEM (Sigma–Aldrich) and the following
components (mM): TRIS acetate, 20; sucrose, 0.27; EDTA, 1;
EGTA, 1; Na Orthovanadate, 1; NaF, 50; Na Pyrophosphate, 5; Na
β-glycerophosphate, 10; DTT, 1.
Samples were then kept for 30min on ice to allow protein sol-
ubilization. Later a centrifugation step of 10min at 12000 rpm
was applied to the samples and the supernatant was collected and
stored at −20◦C until needed.
WESTERN BLOT
Protein concentrations for each sample were determined
by Bradford assay and the samples were directly analyzed
by immunoblotting following resuspension in Laemmli
buffer.
Equal amount of proteins (∼15μg for each condition) were
resolved by 10% SDS-polyacrylamide gels and blotted onto PVDF
membrane (Serva, Germany). The proteins blotted on the mem-
brane were then blocked for 1 h at room temperature using
Tris-buffered saline-Tween (t-TBS) (M) Tris, 0, 02; NaCl, 0, 15;
Tween 20, 0, 1%) containing 5% skimmed milk.
Later the membranes were treated with specific antibod-
ies and the incubation last for 12 h at 4◦C with mild agi-
tation. The primary antibody used for western blot analysis
are: rabbit amyloid precursor protein (AβPP) 1:2000 (Sigma-
Aldrich, USA), rabbit SUMO-1 1:1000 (Cell Signaling, USA),
rabbit SUMO-2/3 (18H8) 1:1000 (Cell Signaling, USA), rabbit
SENP1 1:500 (Thermo scientific, USA), mouse UBC9 (C12)
1:1000 (Santa Cruz Biotechnology, USA), mouse β-actin 1:30000
(Sigma-Aldrich, Italy).
Tris-buffer saline solution (TBS) with 0, 1% of Tween 20
was used to wash the membranes for 50min of wash in t-TBS.
Then the blots were incubated for 1 h at room temperature
with peroxidase-conjugated goat anti-rabbit or anti-mouse IgG
secondary antibodies (UCS Diagnostic), as needed.
After 50min of washes in t-TBS bands immunoreactivity
was detected by enhanced chemiluminescence (ECL; WESTAR,
Cyanagen, Italy). For all experiments stripping procedure was
applied when the control of loading, performed blotting for
β-actin, was required (stripping buffer from SignaGen, USA).
For each time point, a western blot has been performed in
which proteins from six samples for WT and Tg2576 have been
separated and analyzed. Where possible, membranes have been
stripped and re-blotted for different antibodies with the purpose
of using same loading conditions.
RNA EXTRACTION AND REAL-TIME PCR
Total RNA was extracted from brain cortex and hippocampus
using the Trizol reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instruction. RNA yield and purity were deter-
mined by spectrophotometry absorption at 260 and 280 nm. To
obtain cDNA, an equal amount of mRNA (1μg) underwent to
Reverse Transcription (Promega, Madison, WI). The resulting
cDNA was stored at −20◦C until used for the further analy-
sis. Messenger RNA expression was quantitatively measured with
quantitative (q) real time PCR using iCycler Bio-Rad. The reac-
tion was performed in a 25μl volume using SensiMix SYBR
Green and Fluorescein kit (Bioline, London, UK). All the mea-
sures were performed in triplicate. The reaction conditions were
as follows: 95◦C for 10min (Polymerase activation), followed by
40 cycles at 95◦C for 15, 55–50◦C (Temp. depends on the Tm of
primers) for 15 s and 72◦C for 15 s. The reaction mixture without
the cDNA was used as control.
The primer sequences used in this study were as fol-
lowing for SUMO-1: forward 5′-GCCTGGGACATGGGTTT-3′
and reverse 5′-TTAATGAAGCTGGTACAGACGATG-3′; SUMO-
2: forward 5′-GGCAGGGTTTGTCAATGAGGC-3′ and reverse
5′-CTGGAGTAAAGTA GTAGCAGGCTC-3′; SUMO-3: forward
5′-GAGGCAGGGCTTGTCAATGAG-3′ and reverse 5′-GGTC
AGGACAACGGTTGGGTG-3′; SENP1: forward 5′-AATGGCTG
ATGATGATGTG-3′ and reverse 5′-TTGGACAAGGATTAGA
CTGAAT-3′; UBC9: forward 5′-CATCCAGCCTTCGT AAA
CC-3′ and reverse 5′-GCTAACAGGCAGGGAGAT-3′; glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH): forward 5′-GCCA
AGGCTGTGGGCAAGGT-3′ and reverse 5′-TCTCCAGGCGGC
ACGTCAGA-3′.
The Ct values of the specific gene of interest were normalized
to the Ct value of the endogenous control, GAPDH, and the com-
parative Ct method (2−Ct) was then applied using WT mice
group as calibrator.
STATISTICAL ANALYSIS
In the western blots and real time PCR experiments, T-test
analysis was performed and p < 0.05 was considered statisti-
cally significant. Statistical analysis for biochemical experiments
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was performed using GraphPad PRISM 5. A number (as indi-
cated in figure legends) of animal tissues has been used at the
same time point for the experiments. Values shown represent the
mean ± s.e.m. Final western blots have been run using represen-
tative sampling
RESULTS
AβPP INCREASES IN Tg2576 MICE
The Tg2576 transgenic mouse carries a transgene coding for the
695-amino acid isoform of human AβPP derived from a large
Swedish family with early-onset AD (Hsiao et al., 1996). This
mouse model of AD expresses high concentrations of mutant Aβ,
develops a significant number of amyloid plaques, and displays
functional deficits like decreased dendritic spine density, impaired
long-term potentiation (LTP), and behavioral deficits (Jacobsen
et al., 2006; Balducci et al., 2011).
In order to validate the mice model used in this work
we measured AβPP immunoreactivity in the cortical and hip-
pocampal tissues from the brains of Tg2576 and WT mice.
Tg2576 are expected to have an augmented expression of AβPP
because, beside the murine endogenous AβPP, they geneti-
cally over-express human mutated AβPP. Indeed, both cortex
and hippocampus prepared from Tg2576 mice showed a more
intense immunoreactivity of the AβPP band corresponding to
95–100 kDa compared to WT (Figure 1D).
PROTEIN SUMOylation CHANGES IN THE CORTEX OF Tg2576 MICE
DURING ONTOGENESIS
The cerebral cortex is among the most vulnerable brain regions
affected by the disease showing progressive plaque burden and tis-
sue atrophy (Tosun et al., 2011). Although in a less severe manner,
some biochemical hallmarks have also been reported in different
AD mice models (Sclip et al., 2011; Izco et al., 2014).
In order to evaluate protein SUMOylation changes during dis-
ease progression, we dissected and lysated cortical tissues from
1.5, 3, 6, 17 months old Tg2576 and their age-matched WT lit-
termates. Protein SUMOylation has been revealed by western
blotting using an anti-SUMO-1 and an anti-SUMO-2/3 antibody.
SUMO-1 and SUMO2/3 for each time point has been normalized
against the actin. Interestingly, the ratio in protein SUMO-1-
ylation between Tg2576 and WT mice is increased at early stages,
and it later decreases following a bell-shaped curve. In fact, a
peak of SUMO-1-ylation is observed at 3 and 6 months old ani-
mals (Figure 1A, 3 months: 1.65 ± 0.16 p < 0.05; 6 months:
1.78 ± 0.08 p < 0.01).
Noteworthy a protein SUMOylated band, absent in the other
ages analyzed, appears at 6 months of age. The immunoreactivity
of this band results more intense in the Tg2576 mice compared
to controls (Figure 1A, black arrow). Further studies are required
to identify which protein becomes target of SUMO-1 at this stage,
and whether this protein modification has a role in AD pathology.
SUMO-2/3-ylation did not show any differences in the ratio
between Tg2576 and WT mice at different ages except for 17
months old mice, where it resulted drastically decreased in
transgenic mice (Figure 1B, 17 months: 0.35 ± 0.05 p < 0.01).
Further experiments are required to understand what implica-
tion this reduction may have. As for the SUMO-1 western blot,
also for SUMO-2/3 a more intense band is detectable (Figure 1B,
black arrow).
PROTEIN SUMOylation CHANGES IN THE HIPPOCAMPUS OF Tg2576
MICE DURING ONTOGENESIS
The hippocampus is the part of the brain that is involved in
memory formation, being one of the first regions to suffer dam-
age in AD. Since Tg2576 show cognitive impairment caused by
hippocampal dysfunction even before the onset of the pathol-
ogy (D’Amelio et al., 2011), we analyzed protein SUMOylation
changes between Tg2576 and WT mice also in this brain area.
Similarly to the cortex, SUMO-1-ylation is increased in the
hippocampus of 3 and 6 months old Tg2576 compared to
WT (Figure 2A, 3 months: 1.71 ± 0.07 p < 0.01; 6 months:
2.07 ± 0.39 p < 0.01).
SUMO-2/3-ylation did not show any differences in the ratio
between Tg2576 and WT mice at different ages except for 17
months old, where surprisingly it resulted decreased in transgenic
mice (Figure 2B, 17 months: 0.65 ± 0.01 p < 0.01). This result
needs more investigation in order to understand its potential
implication in the pathophysiology of AD.
SUMO PATHWAY RELATED PROTEINS IN Tg2576 TRANSGENIC MICE
ONTOGENESIS
The protein conjugation by SUMO occurs through the activ-
ity of four key enzymes which form the SUMOylation pathway.
Among them Ubc9 and SENP1 are the most important since
they are dedicated exclusively to protein SUMOylation. On the
one hand Ubc9 binds and transports SUMO to the target pro-
tein, on the other SENP1 is the isopeptidase that regulates the
deSUMOylation (Droescher et al., 2013; Feligioni and Nisticò,
2013). Ubc9 and SENP1 are critical for the maintenance of
SUMO/deSUMOylation balance, therefore their expression levels
have been assessed by western blotting in cortical and hippocam-
pal tissue from Tg2576 and WT mice. The expression level of the
two proteins has been normalized on actin and the ratio between
Tg2576 and WT has been analyzed.
Interestingly, we found that the expression level of Ubc9 is
modulated both in cortical and hippocampal tissue. In fact, the
western blots show for both WT and Tg2576 an increase of
Ubc9 from 3 to 17 months with a peak at 6 months of age.
Moreover Ubc9 seems to be highly expressed in Tg2576 com-
pared to WT at different ages (Figure 1C, 6 months: 1.57 ± 0.16
p < 0.05) (Figure 2C, 3 months: 1.42 ± 0.24 p < 0.05; 6 months:
2.22 ± 0.37 p < 0.01). Conversely, immunoreactivity of SENP1
seems to be augmented in the cortex of transgenic mice at
3 and 6 months and only at 6 months in hippocampus of
Tg2576 compared to age-matched WT animals (Figure 1C, 3
months: 1.75 ± 0.21 p < 0.05; 6 months: 2.51 ± 0.21 p < 0.01)
(Figure 2C, 6 months: 2.15 ± 0.42 p < 0.01).
SUMO-1-, SUMO-2-, SUMO-3-, SENP1- AND Ubc9-mRNA IN BRAIN
CORTEX AND HIPPOCAMPUS
SUMO-1 mRNA levels in the cortex (Figure 3A) and hippocam-
pus (Figure 4A) of Tg2576 mice at 1.5 months of age were similar
to the levels measured in WT mice, whereas at 6 months of
age their levels were significantly higher than that of WT mice.
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FIGURE 1 | Protein SUMOylation and SUMO-related proteins
expression level in cortical tissue. Representative western blots of
WT and Tg2576 mice cortical tissue lysate. Cortex of WT and
Tg2576 animals was analyzed at four time points (1.5, 3, 6, and 17
months of age). Anti-SUMO-1 (A), anti-SUMO-2/3 (B), anti-Ubc9,
anti-SENP1 (C), and anti-AβPP (D) have been used for the protein
detections. Results are expressed as ratio between Tg2576 and WT.
Data represent means ± s.e.m. of 6 animals for each age. (t-test)
∗∗p < 0.01 or ∗p < 0.05 Tg2576 vs. WT. β-Actin was used as loading
control.
On the contrary, we did not find any significant changes in
SUMO-2, SUMO-3, SENP1, and Ubc9 mRNA levels in the cor-
tex (Figures 3B–E) and hippocampus (Figures 4B–E) of Tg2576
and WT mice at the age of 1.5 and 6 months. The SUMO-1
mRNA increase is in accordance with the elevated level of SUMO-
1-ylation that has been found in cortex and hippocampus at 6
months of age. It seems that SUMO-1 synthesis is augmented in
order to be disposable for conjugation, whereas the Ubc9 and
SENP1 protein levels are sufficient in both tissues to maintain
SUMOylation pathway functional. The SUMO-2 and -3 mRNA
level is in line with protein SUMO-2/3-ylation expression that
resulted unchanged up to 6 months of age.
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FIGURE 2 | Protein SUMOylation and SUMO-related proteins
expression level in hippocampal tissue. Representative western
blots of WT and Tg2576 mice hippocampal tissue lysate.
Hippocampus of WT at four time points (1.5, 3, 6, and 17 months
of age) was compared with their age-matched Tg2576 mice.
Anti-SUMO-1 (A), anti-SUMO-2/3 (B), anti-Ubc9 and anti-SENP1
(C) have been used for protein detections. Results are expressed as
ratio between Tg2576 and WT. Data represent means ± s.e.m. of 6
animals for each age. (t-test) ∗∗p < 0.01 or ∗p < 0.05 Tg2576 vs. WT.
β-Actin was used as loading control.
DISCUSSION
Tg2576micemodel were developed to test the amyloid hypothesis
of AD. These mice model answered partially the question whether
AD pathology comes from the accumulation of Aβ species. Aβ
species, although poorly detectable, can be found in the soluble
form (monomers, dimers, trimmers or oligomers) already at a
young age (<5 months old) (Kawarabayashi et al., 2001; Klingner
et al., 2003; Lesné et al., 2006), but they reach a highly detectable
level around 6–8 months (Hsiao et al., 1996). Insoluble amyloid
plaques start to form at around 9–10 months in hippocampus
and cortex (Hsiao et al., 1996). This model also shows the typical
AD cognitive impairment with a mild onset at 3 months, which
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FIGURE 3 | mRNA expression level of SUMO and SUMO-related proteins
in cortical tissues. Analyses of SUMO-1 (A), SUMO-2 (B), SUMO-3 (C),
SENP1 (D), Ubc9 (E) mRNA expression in brain cortex of Tg2576 and WT
mice at the age of 1.5 and 6 months. The mRNA expression levels,
determined by real-time polymerase chain reaction (RT-PCR), were expressed
in relation to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
presented as fold increase relative to WT animals. Data represent
mean ± s.e.m. of 4 animals. (t-test) ∗p < 0.05 Tg2576 vs. WT.
is exacerbated starting from 6 months of age. However, Tg2576
do not resemble all the features of AD since they do not dis-
play any formation of neurofibrillary tangles, marked neuronal
loss or gross brain atrophy, (Irizarry et al., 1997), but are any-
way a very useful model to study AD amyloid-related pathology
(Deacon et al., 2008).
Several AD-associated proteins undergo SUMO protein mod-
ification, leading to hypothesize that SUMO plays a fundamental
role in AD pathogenesis. Despite that, we still lack information
about how SUMO/deSUMOylation process is altered during
AD onset and development. Therefore a better understand-
ing of SUMO changes during AD pathogenesis could help
to disclose the role of protein modification in the onset of
AD. Notably, McMillan and co-authors (McMillan et al., 2011)
reported that no clear differences in global protein SUMOylation
can be measured in adult Tg2576 (9 months old) vs. their
respective WT.
In this manuscript, we decided to investigate SUMOylation
changes during mice lifespan analyzing four time points.
To our knowledge this is the first ontogenetic study of
SUMO/deSUMOylation profile in an AD model.
Yun and co-authors have shown in in-vitro experiments that
SUMO-1 can be considered a modulator of the synthesis of Aβ
oligomers (Yun et al., 2013). In fact SUMO-1, but not SUMO-2
or -3, when overexpressed in neuronal or cell culture, increases
BACE1 level which mediates the amiloydogenic cleavage of AβPP.
Moreover, as previously reported in 18 months old AβPP trans-
genic mice (Yun et al., 2013) SUMO-1 free protein is increased in
their cortical tissue. So, it has been postulated that the increase of
Aβ accumulation together with an accrual of cell oxidative stress
can act synergistically to enhance protein SUMO-1-ylation. By
conjugating BACE1, SUMO-1 intensifies Aβ oligomers produc-
tion (Yun et al., 2013). Our data show that already at the age of
3 months, protein SUMO-1-ylation is augmented both in corti-
cal and hippocampal tissue of Tg2576 model compared to their
respective WT.
Therefore it can be hypothesized that at early stages (3
months) the “cell stress” might contribute more to the increase
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FIGURE 4 | mRNA expression level of SUMO and SUMO-related proteins
in hippocampal tissues. Analyses of SUMO-1 (A), SUMO-2 (B), SUMO-3
(C), SENP1 (D), Ubc9 (E) mRNA expression in brain hippocampus of Tg2576
and WT mice at the age of 1.5 and 6 months. The mRNA expression levels,
determined by real-time polymerase chain reaction (RT-PCR), were expressed
in relation to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
presented as fold increase relative to WT animals. Data represent
mean ± s.e.m. of 4 animals. (t-test) ∗p < 0.05 Tg2576 vs. WT.
in SUMO-1-ylation compared to Aβ oligomers which are present
at low levels at this age. As a result, SUMO-1-ylation activates
multiple signaling pathways, like BACE1, GSK3β, JNK activation,
that can contribute to boost the production of Aβ oligomers. The
feedback loop established between SUMO-1, Aβ oligomers and
cell stress cooperate to the development of AD neuropathology.
Interestingly, SUMO-2-ylation does not change between Tg2576
andWT except for 17months old transgenicmice where it is dras-
tically diminished both in cortex and hippocampus. This aspect
also deserves a deeper investigation since very little is known
about SUMO-2/3 contribution to AD.
Ubc9 and SENP1 are critical enzymes for protein
SUMOylation (Droescher et al., 2013; Feligioni and Nisticò,
2013). An increase of SUMOylation is associated with the onset
of several pathologies including cancer. For example, Ubc9
expression, the E2 enzyme which facilitates SUMOylation, has
been reported increased in primary colon and prostate cancer
compared with normal tissue (Moschos et al., 2010). We here
demonstrate that the increase of SUMOylation in Tg2576 brain
tissues corresponds to a high expression level of Ubc9 at the
same time points. Therefore Ubc9 plays a fundamental role
for SUMOylation event also in AD. On the other hand, the
over-functionality of SUMOylation in Tg2576 is also supported
by an elevated presence of the SUMO protease SENP1. Our
results are in line with previous data where SENP-1 was found
increased during oxygen-glucose deprivation (OGD) experi-
ments, suggesting that the neuronal response could involve a
complex interplay between SUMOylation and deSUMOylation
(Cimarosti et al., 2012).
The analysis of mRNA expression has shown an increase of
SUMO-1 RNA only at the age of 6 months both in cortex and
hippocampus. This is in line with our western blot data where the
major increase of SUMOylation was exactly found at 6 months
of age in Tg2576 mice, where probably there is a need for more
protein synthesis. In contrast, although we reported an increase
in protein expression level of both Ubc9 and SENP1, the mRNA
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expression of both proteins was unchanged. We can therefore
speculate that the degradation system of Ubc9 and SENP1 could
be decreased during lifespan of mice. Further studies should be
carried out in order to better clarify this aspect. In line with a pre-
vious work (McMillan et al., 2011), our experiments did not show
significant changes in protein SUMO-2/3-ylation in AD mice up
to 6 months of age. SUMO-2/3 role in AD remains still elusive.
However, in in-vitro experiments it has been shown that SUMO-
2 increases N-terminal ADAM-cleaved AβPP fragment (α-NTF)
while a mutant form of SUMO-2 lacking the SUMOylation activ-
ity secreted significantly more N-terminal BACE1-cleaved AβPP
fragment (β-NTF) and Aβ (Li et al., 2003). In line with this report,
we can speculate that the reduction in protein SUMO-2/3-ylation
that was observed in 17 months old Tg2576 mice is concomitant
with an elevated amyloid deposition which occurs at this stage
in AD mice model (Jacobsen et al., 2006). In conclusion, here
we report for the first time that protein SUMO/deSUMOylation
equilibrium is unbalanced in a mouse model of AD at a very early
stage of the pathology. We believe that this event can contribute
to the onset of AD pathogenesis. Future investigation on the tar-
get(s) of protein SUMOylation at an early stage could possibly
lead to the identification of novel pharmacological targets.
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